June 24, 2016 4:45pm

A number of my favorites took hits, now might be the time to pick up “some” shares at a “Brexit” discount, which is the smart play when investors are panicking

 

Done is done, what should investors do as the Russell rebalances, Q2 nears its end – tread carefully focused on companies with solid cash positions

Development platforms are also being de-leveraged by access to capital markets

 

There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.

 

Do you care what happened today, you should … because it has implications to Monday's sector activity?  

 

 

U.S. stocks traded sharply lower Friday in a global risk-off trade after Britain surprised markets by voting to leave the European Union.

The NASDAQ closed DOWN -202.06 or -4.12% to 4,707.98 and the DOW closed DOWN -610.80 or -3.38% to 17,400.27.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:    

  • The open was negative with an A/DL of 32/9 and 2 flats;
  • The mid-day stayed negative with an A/DL of 34/8 and 1 flat;
  • The closing bell was negative  with A/DL of 5/37 and 1 flat;

 

 

Ending the day and the week:

What we are seeing in the stem, cell, gene and regenerative therapy sector is the repricing of risk with heightened uncertainty – but, still an overreaction.

 

 

Henry’omics:

What hasn’t been said by many in every headline around the world …?

The SCGT&RT sector opened negative, stayed negative at the mid-day and closed negative.

  • Among the stocks showing more upside volume are Caladrius Biosciences (CLBS), Fibrocell (FCSC), Fate Therapeutics (FATE), Cytori (CYTX) and Opexa (OPXA)
  • Shares demonstrating downside volume were Athersys (ATHX), Northwest Bio (NWBO), Juno Therapeutics (JUNO), ReNeuron (RENE.L) and Aduro Biotech (ADRO)

Regardless which way the U.K. referendum on membership in the European Union turns out, U.S. investors are likely to shift their attention to our own financial markets once the Brexit-induced turbulence fades away.

 

The next issue is Q2 results and spending versus depleting cash positions.

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

  • Friday traded above 23;
  • Thursday traded 17.4;
  • Wednesday topped 21;
  • Tuesday traded near 18.2;
  • Monday traded near 18;
  • Last, Friday traded near 19.3;

 

 

Most active sector stocks + and -:

  • Neuralstem (CUR) -9.99%
  • Regenxbio (RGNX) -9.27%;
  • Adverum (ADVM) -9.01%:
  • StemCells (STEM) -8.33%;
  • Northwest Bio (NWBO) -7.95%;

versus:

  • Fibrocell (FCSC) +5.89%;
  • Opexa (OPXA) +3.36%;
  • Fate Therapeutics (FATE) +2.38%;
  • Caladrius Biosciences (CLBS) +2.83%;
  • Cytori (CYTX) +1%

Flat:

  • International Stem Cell (ISCO) at $2.05

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.